Abstract
No public abstract is available from the verified source records.
Liu Gang, Alena Mikalaeuna Vasiukevich
Abstract
Authors
Institutions
Provenance
crossref
Confidence 100%
openalex
Confidence 95%
datacite
Confidence 0%
No local reference links have been materialized yet.
No local citing links have been materialized yet.
Systemic lupus erythematosus
10.1056/nejmra1100359 · 2011
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus
2011
Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial
2010
Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study
2012
Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia
2018
Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma
2017
Long-term follow-up of anti-CD19 chimeric antigen receptor T-cell therapy
2020
CD19-targeted CAR T cells in refractory systemic lupus erythematosus
10.1056/nejmc2107725 · 2021
Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus
2022
CD19-targeted CAR T cells in refractory antisynthetase syndrome
2023
Anti-CD19 CAR T cells for refractory myasthenia gravis
2023
Global manufacturing of CAR T cell therapy
2017
Preparing for CAR T cell therapy: patient selection, bridging therapies and lymphodepletion
2022
Clonal expansion of CAR T cells harboring lentivector integration in the CBL gene following anti-CD22 CAR T-cell therapy
2019
Value and affordability of CAR T-cell therapy in the United States
2020
Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine
2020
In vitro-transcribed antigen receptor mRNA nanocarriers for transient expression in circulating T cells in vivo
2020
Ionizable lipid nanoparticle-mediated mRNA delivery for human CAR T cell engineering
2020
Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs
2021
Unresolved referenced work
2022
CAR T cells produced in vivo to treat cardiac injury
2022
Aberrant T cell signaling and subsets in systemic lupus erythematosus
10.3389/fimmu.2018.01088 · 2018
Sustained B cell depletion by CD19-targeted CAR T cells is a highly effective treatment for murine lupus
2019
Aberrant T cell signaling and subsets in systemic lupus erythematosus
10.3389/fimmu.2018.01088 · doi-reference
CD19-targeted CAR T cells in refractory systemic lupus erythematosus
10.1056/nejmc2107725 · doi-reference
Systemic lupus erythematosus
10.1056/nejmra1100359 · doi-reference